Human Signal Regulatory Protein Alpha (Sirp Alpha Variant V2 Extracellular D1 Domain, Sirp Alpha V2D1) Fragment 31-163, Comprising The First Two Extracellular Loops Of The D1 Domain, [N<Sup>110</Sup>>A<Sup>80</Sup>]-Variant, Anti-(Human Cd47, Integrin Associated Protein (Iap)) (1-133 In The Current Sequence) Fused Via A (G4S) 2 Peptide Linker (134-143) To Gamma 1 Heavy Chain (144-594) [Vh (Mus Musculus Ighv1-12*01 -(Ighd) -Ighj1*01, Cdr-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo Sapiens Ighg1*03(Ch1 (265-362), Hinge (363-377), Ch2 S<Sup>445</Sup>>A, E<Sup>480</Sup>>A, K <Sup>481</Sup>>A (378-487), Ch3 (488-592), Chs (593-594)) (265-594)], (367-213')-Disulfide With Kappa Light Chain (1'-213') [V-Kappa (Mus Musculus Igkv4-72*01 -Igkj1*01, Cdr-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo Sapiens Igkc*01 (107'-213')]; Dimer (373-373'':376-376'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
B-Cell Non-Hodgkin Lymphoma
Explore 306 assets in B-Cell Non-Hodgkin Lymphoma →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05771883CT.gov A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide | — | Unknown | — | — | — |
NCT04746131CT.gov Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) | — | Suspended | — | — | — |
NCT05805943CT.gov Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Signal Regulatory Protein Alpha (Sirp Alpha Variant V2 Extracellular D1 Domain, Sirp Alpha V2D1) Fragment 31-163, Comprising The First Two Extracellular Loops Of The D1 Domain, [N<Sup>110</Sup>>A<Sup>80</Sup>]-Variant, Anti-(Human Cd47, Integrin Associated Protein (Iap)) (1-133 In The Current Sequence) Fused Via A (G4S) 2 Peptide Linker (134-143) To Gamma 1 Heavy Chain (144-594) [Vh (Mus Musculus Ighv1-12*01 -(Ighd) -Ighj1*01, Cdr-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo Sapiens Ighg1*03(Ch1 (265-362), Hinge (363-377), Ch2 S<Sup>445</Sup>>A, E<Sup>480</Sup>>A, K <Sup>481</Sup>>A (378-487), Ch3 (488-592), Chs (593-594)) (265-594)], (367-213')-Disulfide With Kappa Light Chain (1'-213') [V-Kappa (Mus Musculus Igkv4-72*01 -Igkj1*01, Cdr-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo Sapiens Igkc*01 (107'-213')]; Dimer (373-373'':376-376'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa (this asset) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | P1/2 | CCC · 52 |
| Vindesine | Children's Cancer Group, China | P4 | BBB |
| Anti-Cd20/Cd3 Monoclonal Antibody Regn1979 | University of Birmingham | P3 | BBB |
| Cytarabine | Children's Cancer Group, China | P4 | BBB |
| Camustine | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BBB |
| Zanubrutinib | The First Affiliated Hospital of Soochow University | P4 | BBB |
| Isocyclophosphamide | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Transduced With A Nonreplicative Self-Inactivating (Sin) Lentiviral Vector Encoding A Chimeric Antigen Receptor (Car) Consisting Of The Human Cd19-Specific Scfv, An Lgg4 Hinge Region, Cd28 Transmembrane Domain, Cd137 (4-1Bb) Co-Stimulatory Domain And Cd3 Zeta Signalling Domain, Under The Control Of A Hybrid Elongation Factor 1 Alpha (Ef1.Alpha.) And Human T Cell Leukemia Virus Type 1(Htlv-1) Regulatory Element Promoter And Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element (Wpre). The Vector Genome Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Co-Expressed With The Car And Cleaved From It By The T2A Self-Cleaving Peptide. The Vector Genome Also Contains A Splice Donor, A Fragment Of Gag, A Rev Response Element (Rre), A Mutated Central Polypurine Tract (Cppt), And A Splice Acceptor | Ruijin Hospital | P4 | BBB |
| Tacrolimus | M.D. Anderson Cancer Center | P2 | BB |
+42 more in the B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Human Signal Regulatory Protein Alpha (Sirp Alpha Variant V2 Extracellular D1 Domain, Sirp Alpha V2D1) Fragment 31-163, Comprising The First Two Extracellular Loops Of The D1 Domain, [N<Sup>110</Sup>>A<Sup>80</Sup>]-Variant, Anti-(Human Cd47, Integrin Associated Protein (Iap)) (1-133 In The Current Sequence) Fused Via A (G4S) 2 Peptide Linker (134-143) To Gamma 1 Heavy Chain (144-594) [Vh (Mus Musculus Ighv1-12*01 -(Ighd) -Ighj1*01, Cdr-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo Sapiens Ighg1*03(Ch1 (265-362), Hinge (363-377), Ch2 S<Sup>445</Sup>>A, E<Sup>480</Sup>>A, K <Sup>481</Sup>>A (378-487), Ch3 (488-592), Chs (593-594)) (265-594)], (367-213')-Disulfide With Kappa Light Chain (1'-213') [V-Kappa (Mus Musculus Igkv4-72*01 -Igkj1*01, Cdr-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo Sapiens Igkc*01 (107'-213')]; Dimer (373-373'':376-376'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Follicular Lymphoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- VindesineChildren's Cancer Group, ChinaBBB
- Anti-Cd20/Cd3 Monoclonal Antibody Regn1979University of BirminghamBBB
- CytarabineChildren's Cancer Group, ChinaBBB
- CamustineFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBBB
- ZanubrutinibThe First Affiliated Hospital of Soochow UniversityBBB
Citation
Floatz Terminal. Human Signal Regulatory Protein Alpha (Sirp Alpha Variant V2 Extracellular D1 Domain, Sirp Alpha V2D1) Fragment 31-163, Comprising The First Two Extracellular Loops Of The D1 Domain, [N<Sup>110</Sup>>A<Sup>80</Sup>]-Variant, Anti-(Human Cd47, Integrin Associated Protein (Iap)) (1-133 In The Current Sequence) Fused Via A (G4S) 2 Peptide Linker (134-143) To Gamma 1 Heavy Chain (144-594) [Vh (Mus Musculus Ighv1-12*01 -(Ighd) -Ighj1*01, Cdr-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo Sapiens Ighg1*03(Ch1 (265-362), Hinge (363-377), Ch2 S<Sup>445</Sup>>A, E<Sup>480</Sup>>A, K <Sup>481</Sup>>A (378-487), Ch3 (488-592), Chs (593-594)) (265-594)], (367-213')-Disulfide With Kappa Light Chain (1'-213') [V-Kappa (Mus Musculus Igkv4-72*01 -Igkj1*01, Cdr-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo Sapiens Igkc*01 (107'-213')]; Dimer (373-373'':376-376'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-signal-regulatory-protein-alpha-sirp-alpha-variant-v2-extracellular-d1-domain-sirp-alpha-v2d1-fragment-31-163-comprising-the-first-two-extracellular-loops-of-the-d1-domain-nsup110supasup80sup-variant-anti-human-cd47-integrin-associated-protein-iap-1-133-in-the-current-sequence-fused-via-a-g4s-2-peptide-linker-134-143-to-gamma-1-heavy-chain-144-594-vh-mus-musculus-ighv1-1201-ighd-ighj101-cdr-kabat-51712174-178193-209242-253-144-264-homo-sapiens-ighg103ch1-265-362-hinge-363-377-ch2-ssup445supa-esup480supa-k-sup481supa-378-487-ch3-488-592-chs-593-594-265-594-367-213-disulfide-with-kappa-light-chain-1-213-v-kappa-mus-musculus-igkv4-7201-igkj101-cdr-kabat-1079-24-3349-5588-96-1-106-homo-sapiens-igkc01-107-213-dimer-373-373376-376-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-cell-line-cho-k1-glycoform-alfa-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →